17th May 2019 - The Global Acute
Heart Failure (AHF) Therapeutics Market is anticipated to rise at a
staggering CAGR during the forecast period. Acute heart failure syndromes
comprise a broad range of clinical representations to patient conditions in
some aspect of cardiac function. It represents a wider array of pathologies,
treatment and a chronic heart condition.
Acute
heart failure (AHF) is a common heart condition resulting out of acute and
chronic heart conditions leading to cardiac function. However, while the
patient opts for treatment, haemodynamic parameters, ventricular function,
end-organ perfusion and respiratory function can vary. In such conditions,
tailored treatment proves to be the best choice for patients with acute heart
failure conditions.
Request a Sample Copy
of this Report @ https://www.millioninsights.com/industry-reports/acute-heart-failure-ahf-therapeutics-market/request-sample
By
disorder type, acute heart failure (AHF) therapeutics market is segmented as
left-sided heart failure, right-sided heart failure, diastolic failure and
systolic failure. Drug category segment comprises angiotensin II receptor
blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin-receptor
neprilys in inhibitors and beta-blockers. Distribution channel segment for
acute heart failure (AHF) therapeutics market comprises retail pharmacies,
online pharmacies and hospital pharmacies. Hospital pharmacies account for a
significant market share due to rise in demand
Geographical
segmentation for market is North America, Latin America, Europe, Asia-Pacific,
Middle East and Africa. North America is likely to gain a significant CAGR
during the forecast period due to increase in prevalence of acute heart disease
failure cases and increase in prevalence of obesity. Sedentary lifestyle and
high risk of heart disease triggers the market demand for heart failure
therapeutics.
Asia-Pacific regions are more likely to gain a significant
share in international market due to availability of medical infrastructure and
rise in number of heart patients are contributing to the regional market
growth. European market follows the trend. The key players profiled in the
acute heart failure (AHF) therapeutics market report are Bristol-Myers Squibb
Company, Amgen Inc, Cytokinetics Inc, Merck & Company, Pfizer Inc, Ono
Pharmaceutical Co Ltd, Novartis AG and Cardiorentis AG.
No comments:
Post a Comment